210 related articles for article (PubMed ID: 12003419)
1. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
Dore MP; Graham DY; Mele R; Marras L; Nieddu S; Manca A; Realdi G
Am J Gastroenterol; 2002 Apr; 97(4):857-60. PubMed ID: 12003419
[TBL] [Abstract][Full Text] [Related]
2. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
[TBL] [Abstract][Full Text] [Related]
3. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
[TBL] [Abstract][Full Text] [Related]
4. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
5. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
Thijs JC; van Zwet AA; Moolenaar W; Wolfhagen MJ; ten Bokkel Huinink J
Am J Gastroenterol; 1996 Jan; 91(1):93-7. PubMed ID: 8561152
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Marko D; Calvet X; Ducons J; Guardiola J; Tito L; Bory F;
Helicobacter; 2005 Feb; 10(1):22-32. PubMed ID: 15691312
[TBL] [Abstract][Full Text] [Related]
7. 4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
de Boer WA; van Etten RJ; Schade RW; Ouwehand ME; Schneeberger PM; Tytgat GN
Am J Gastroenterol; 1996 Sep; 91(9):1778-82. PubMed ID: 8792697
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
[TBL] [Abstract][Full Text] [Related]
9. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
[TBL] [Abstract][Full Text] [Related]
10. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.
de Boer WA; van Etten RJ; Schneeberger PM; Tytgat GN
Am J Gastroenterol; 2000 Mar; 95(3):641-5. PubMed ID: 10710051
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone.
Nijevitch AA; Shcherbakov PL; Sataev VU; Khasanov RSh; Al Khashash R; Tuygunov MM
Aliment Pharmacol Ther; 2005 Nov; 22(9):881-7. PubMed ID: 16225499
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
13. Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Calvet X; García N; Campo R; Brullet E; Comet R; Navarro M
Am J Gastroenterol; 1998 Jun; 93(6):932-4. PubMed ID: 9647022
[TBL] [Abstract][Full Text] [Related]
14. The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Janssen MJ; Laheij RJ; Jansen JB; de Boer WA
Neth J Med; 2004 Jun; 62(6):192-6. PubMed ID: 15460498
[TBL] [Abstract][Full Text] [Related]
15. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study.
Katelaris PH; Forbes GM; Talley NJ; Crotty B
Gastroenterology; 2002 Dec; 123(6):1763-9. PubMed ID: 12454831
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Dore MP; Marras L; Maragkoudakis E; Nieddu S; Manca A; Graham DY; Realdi G
Helicobacter; 2003 Aug; 8(4):307-9. PubMed ID: 12950603
[TBL] [Abstract][Full Text] [Related]
19. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Liu CC; Lee CL; Chan CC; Tu TC; Liao CC; Wu CH; Chen TK
Arch Intern Med; 2003 Sep; 163(17):2020-4. PubMed ID: 14504114
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
Perri F; Festa V; Clemente R; Villani MR; Quitadamo M; Caruso N; Bergoli ML; Andriulli A
Am J Gastroenterol; 2001 Jan; 96(1):58-62. PubMed ID: 11197288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
